Adagio Therapeutics Inc

NASDAQ:ADGI   3:59:54 PM EDT
2.71
+0.09 (+3.44%)
Products, Expansion, Regulatory

Adagio Therapeutics Announces Expansion Of Patient Population In Global Phase 2/3 Clinical Trial Of ADG20 For Prevention Of Covid-19

Published: 09/10/2021 11:18 GMT
Adagio Therapeutics Inc (ADGI) - Adagio Therapeutics Announces Expansion of Patient Population in Global Phase 2/3 Clinical Trial of Adg20 for the Prevention of Covid-19.
Adagio Therapeutics - Idmc for Evade Phase 2/3 Trial of Adg20 Recommended to Expand Phase 3 Trial Enrollment to Include Adolescents, Pregnant/nursing Women.
Adagio Therapeutics Inc - Idmc for Evade Phase 2/3 Trial of Adg20 Recommended to Decrease Protocol-specified, Post Injection Monitoring Time.
Adagio Therapeutics Inc - Plans to Implement Idmc Recommendations for Phase 3 Portion of Trial.